Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 11/2017

01-11-2017 | Letter to the Editor

Somatic mutations of calreticulin in patients with myelodysplastic/myeloproliferative neoplasms-unclassifiable

Authors: Xueya Zhang, Jingxin Pan

Published in: Annals of Hematology | Issue 11/2017

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (2008) WHO classification of tumors of haematopoietic and lymphoid tissues, 4th edn. IARC, Lyon, pp 75–86
2.
Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369:2379–2390CrossRefPubMed
3.
Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369:2391–2405CrossRefPubMedPubMedCentral
4.
Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D et al (2014) Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood 123:2645–2651CrossRefPubMedPubMedCentral
5.
Barraco D, Lasho TL, Gangat N, Finke C, Elala YC, Pardanani A et al (2016) Leukocytosis and presence of CALR mutation is associated with non-hepatosplenicextramedullary hematopoiesis in primary myelofibrosis. Blood Cancer J 6:e436CrossRefPubMedPubMedCentral
6.
Orazi A, Germing U (2008) The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia 22:1308–1319CrossRefPubMed
7.
DiNardo CD, Daver N, Jain N, Pemmaraju N, Bueso-Ramos C, Yin CC et al (2014) Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history andclinical outcome by treatment strategy. Leukemia 28:958–961CrossRefPubMedPubMedCentral
Metadata
Title
Somatic mutations of calreticulin in patients with myelodysplastic/myeloproliferative neoplasms-unclassifiable
Authors
Xueya Zhang
Jingxin Pan
Publication date
01-11-2017
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 11/2017
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-017-3100-0

Other articles of this Issue 11/2017

Annals of Hematology 11/2017 Go to the issue

Original Article

Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS)

Original Article

Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy

Letter to the Editor

Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia

Letter to the Editor

A novel heterozygous ALAS2 mutation in a female with macrocytic sideroblastic anemia resembling myelodysplastic syndrome with ring sideroblasts: a case report and literature review

Original Article

A cross-sectional study on late taste disorders in survivors of allogeneic hematopoietic cell transplantation

Original Article

Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits